Neuberger Berman Group
CTMX icon

Neuberger Berman Group’s CytomX Therapeutics CTMX Stock Holding History

Neuberger Berman Group’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-7,735
Closed -$220K – 1714
2018
Q1 		$220K Buy
+7,735
New +$221K ﹤0.01% 1590
2016
Q4 		– Sell
-14,300
Closed -$224K – 1599
2016
Q3 		$224K Buy
+14,300
New +$173K ﹤0.01% 1483

Other funds holding CTMX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

Neuberger Berman Group's CTMX Position: Q2 2018 in Review

Neuberger Berman Group sold out of CytomX Therapeutics (CTMX) in Q2 2018, closing a stake of 7,735 shares — an estimated $220K sold.

Neuberger Berman Group first reported a position in CTMX in Q3 2016 and held it in 2 quarters. The position peaked at $224K in Q3 2016. 142 funds tracked by Wall St. Rank hold CTMX as of Q2 2018.

  • Neuberger Berman Group reported no remaining CytomX Therapeutics position as of Q2 2018 after selling out during the quarter.
  • Neuberger Berman Group sold 7,735 CytomX Therapeutics shares in Q2 2018, an estimated $220K.
  • Neuberger Berman Group first reported a position in CytomX Therapeutics in Q3 2016 and held it in 2 quarters.
  • Neuberger Berman Group's CytomX Therapeutics position peaked at $224K in Q3 2016.
  • 142 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q2 2018.

Based on Neuberger Berman Group's 13F filing for Q2 2018, filed 13 Aug 2018.